X4 Pharmaceuticals, Inc
XFORHeld by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase3 readout (Mavorixafor): Dec 2025. Short interest: 4.4% of float.
Held by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase3 readout (Mavorixafor): Dec 2025. Short interest: 4.4% of float.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.